Michelle Shea

Papers

Total Citations

H-Index

About

Michelle Shea is a pioneering researcher in the field of ADME/Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) screening, a critical area in early-stage drug development. Her major contributions center on the development and validation of high-throughput microfluidic assays for assessing key pharmacokinetic properties of drug candidates. Shea’s most cited work, including her 2003 paper on Tecan’s LabCD-ADMET system, demonstrates her expertise in integrating three essential assays—Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—onto a compact, automated platform. This innovation streamlined the drug discovery pipeline by enabling rapid, simultaneous evaluation of compound safety and efficacy. With citations totaling 15 for this foundational work, Shea’s research has provided a practical framework for reducing late-stage drug failures. Her achievements highlight a commitment to bridging microfluidics and pharmacology, making her a notable figure in advancing preclinical screening technologies. For students and researchers, Shea’s work exemplifies how targeted assay development can accelerate the identification of viable therapeutic candidates.